PITTSBURGH, June 04, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet need, today announced that it has re-signed its manufacturing collaboration agreement with Cook MyoSite, Inc. (“Cook MyoSite”) to support Chemistry, Manufacturing… Read More..

Study met primary endpoint of ≥15-letter (≥3-line) gain in mesopic low contrast distance visual acuity in comparison to placebo Phase 3 study showed patient-reported functional benefit in treating significant, chronic night driving impairment in keratorefractive patients with reduced mesopic vision, a condition with no current FDA-approved therapies Safety profile consistent… Read More..

FT. LAUDERDALE, Fla., May 29, 2025 (GLOBE NEWSWIRE) -- EdgeMode Inc. (OTC: EDGM), today announced the successful acquisition of Synthesis Analytics Production Ltd. (SAPL), a strategic step in the company’s expansion into the high-performance computing AI-focused data center market. The acquisition which closed on April 7, 2025, provides EdgeMode with… Read More..